Literature DB >> 6344847

Diabetic rubeosis and panretinal photocoagulation.

P R Pavan, J C Folk, T A Weingeist, V M Hermsen, R C Watzke, P R Montague.   

Abstract

Iris fluorescein angiography was used to perform the first prospective, controlled, masked evaluation of the effect of panretinal photocoagulation on diabetic rubeosis. Eyes with rubeosis had iris fluorescein angiograms five to seven weeks apart. Eyes either had laser treatment immediately after the first angiogram or had no laser treatment between angiograms. The rubeosis was said to have improved if all three masked readers independently selected the angiogram performed last as having the less severe rubeosis. In eyes with severe rubeosis, only two of 11 (18%) spontaneously improved whereas 11 of 15 (73%) improved following laser therapy. In eyes with mild rubeosis, one of ten improved spontaneously and one of ten improved following laser therapy. Iris fluorescein angiography documented regression of severe but not mild rubeosis following panretinal photocoagulation.

Entities:  

Mesh:

Year:  1983        PMID: 6344847     DOI: 10.1001/archopht.1983.01040010882003

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  The medical check-up for potentially serious diabetic retinopathy.

Authors:  I S Begg
Journal:  Can Fam Physician       Date:  1986-07       Impact factor: 3.275

2.  The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).

Authors:  Peter A Netland
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

3.  Fluorescein gonioangiography in diabetic neovascularisation.

Authors:  Y Ohnishi; T Ishibashi; T Sagawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

4.  Efficacy and Safety of Combined Surgeries including Intraocular Direct Cyclophotocoagulation with a 532 nm Laser to Treat Advanced Neovascular Glaucoma.

Authors:  Xiaomin Chen; Tian Zheng; Wen Zeng; Xia Fu; Shun Wang; Weijuan Zeng; Min Ke
Journal:  J Ophthalmol       Date:  2021-07-07       Impact factor: 1.909

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.